Chest
-
Critical Care Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Mirtazapine is an anti-depressant that is known to have minimal gastrointestinal side effects. There are only four case reports describing mirtazapine associated pancreatitis and one associated with hypertriglyceridemia. This case is of a woman who was admitted to the ICU with hypertriglyceridemia associated pancreatitis and subsequent diabetic ketoacidosis secondary to her use of Remeron. ⋯ The following authors have nothing to disclose: Jeffrey Stone, Nitin PuriNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Interstitial Lung Disease CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: The course of adult Pulmonary Langerhans cell Histiocytosis (PLCH) is variable and unpredictable [1]. Conventional therapy is mainly based on smoking cessation. If the patient is severely symptomatic or the disease shows radiological or physiological deterioration after a short observation period, a course of steroids should be given. Chemotherapeutic drugs,like 2-chlorodeoxyadenosine, may be effective in childhood forms of disseminated LCH, but there is far too little experience with these agents in adult pulmonary LCH patient [1]. ⋯ The following authors have nothing to disclose: Juan Cruz Rueda, Julián Ceballos Gutiérrez, Ana Fulgencio, Jose Manuel Gonzalez de Vega, Ana Dolores Romero OrtizNo Product/Research Disclosure Information.
-
PleuralSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: Evaluate whether thoracentesis is necessary in all parapneumonic effusions regardless of volume ⋯ The following authors have nothing to disclose: Maria Galarza Jimenez, Deisy Barrios Barreto, Esteban Perez Rodriguez, Carolina Gotera, Patricia Lazo Meneses, Carolina Jurkojc Mohremberger, Salvador Diaz Lobato, Sagrario Mayoralas AlisesNo Product/Research Disclosure Information.
-
Respiratory Support PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: COPD is a major cause of morbidity and mortality worldwide, representing a major public health problem due to the high health and economic resource consumption. Pulmonary rehabilitation is a standard care recommendation for these patients, in order to control the symptoms and optimize the functional capacity, reducing healthcare costs associated with exacerbations and activity limitations and participation. However, in patients with severe COPD exercise performance can be difficult, due to extreme dyspnea, decreased muscle strength and fatigue. In addition, hypoxemia and dyspnea during efforts and daily activities may occur, limiting their quality of life. Thus, NIV have been used as adjunct to exercise, in order to improve exercise capacity in these patients. However, there is no consensus for this technique recommendation. Our objective was to verify whether the use of NIV during exercise is effective than exercise without NIV in dyspnea, walked distance, blood gases and health status in COPD patients, through a systematic review and meta-analysis. ⋯ Sara Correia: Employee: salary The following authors have nothing to disclose: Teresa Tomás, Elisabete CarolinoNo Product/Research Disclosure Information.